CriticalSelective serotonin reuptake inhibitor (SSRI)×First-generation antipsychotic, diphenylbutylpiperidine derivative
Updated · Methodology
Mechanism
The liver clears pimozide mainly through the enzymes CYP3A4 and CYP2D6, and paroxetine inhibits CYP2D6 (pimozide and paroxetine summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After a single 2 mg dose of pimozide with paroxetine 60 mg daily, pimozide exposure (area under the curve) rose by 151% on average and its peak concentration by 62% (pimozide SmPC, AEMPS; pimozide label, US Food and Drug Administration, FDA). Pimozide has a narrow therapeutic range and prolongs the QT interval itself, so higher levels raise the risk of QT prolongation and ventricular arrhythmias (paroxetine and pimozide SmPCs, AEMPS). Rarely, serotonin syndrome or neuroleptic malignant syndrome develops when paroxetine is combined with neuroleptics (paroxetine SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). An arrhythmia causes palpitations, dizziness and fainting. With pimozide, reports include QT prolongation, torsade de pointes, ventricular tachycardia and ventricular fibrillation (sometimes fatal), cardiac arrest and sudden death (pimozide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Oculogyric crisis, an attack of forced upward eye deviation, has been associated with paroxetine taken with pimozide. Other extrapyramidal reactions to paroxetine include akathisia, slowed movement and cogwheel rigidity (paroxetine label, US Food and Drug Administration, FDA). Neuroleptic malignant syndrome causes fever, generalised muscle rigidity, unstable blood pressure and pulse and altered consciousness (pimozide SmPC, AEMPS). Serotonin syndrome causes agitation, confusion, hallucinations, sweating, chills, fast heart rate, tremor, muscle jerks and brisk reflexes (paroxetine SmPC, AEMPS).
Management
The combination is contraindicated (paroxetine and pimozide summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US Food and Drug Administration (FDA) pimozide label also contraindicates pimozide with paroxetine and other strong CYP2D6 inhibitors (pimozide FDA label). Switching to another selective serotonin reuptake inhibitor (SSRI) does not help: sertraline, citalopram and escitalopram are also contraindicated with pimozide (pimozide SmPC, AEMPS). Fluoxetine may slow pimozide clearance through CYP2D6, so the same contraindication for CYP2D6 inhibitors covers it (pimozide SmPC, AEMPS). Do not use pimozide with other QT-prolonging drugs, with low potassium or magnesium, or with clinically significant bradycardia (pimozide SmPC, AEMPS). Record an electrocardiogram (ECG) before starting pimozide and repeat it during treatment (pimozide SmPC, AEMPS). If QT prolongation, T-wave changes, U waves or arrhythmias appear, lower the pimozide dose or stop it. Stop pimozide if the QT or corrected QT interval (QTc) exceeds 500 ms (pimozide SmPC, AEMPS). Correct low potassium before starting pimozide and keep it normal throughout treatment (pimozide FDA label). If serotonin syndrome or neuroleptic malignant syndrome appears, stop paroxetine and start supportive treatment (paroxetine SmPC, AEMPS). In neuroleptic malignant syndrome, stop pimozide at once as well (pimozide SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Pimozide tablets, USP (ANI Pharmaceuticals) – prescribing information (2026)– FDA label, ANI Pharmaceuticals, DailyMed setid 4e954fc2-fdff-486c-beb6-2b8ace717081, version 3, 07/2026, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- FDA: Paxil (paroxetine) prescribing information (2026)– Apotex Corp. PAXIL (paroxetine) tablets. Prescribing information, DailyMed setid ef3b5cbe-f9e1-c1ac-79da-cfe14e3a7e7e, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Orap (pimozida) (nº registro 49503), sección 4.3 (2026)– AEMPS, CIMA, nº registro 49503, revisión 10/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Paroxetina (nº registro 59466), sección 4.3 (2025)– AEMPS, CIMA, nº registro 59466 (Frosinor 20 mg, GlaxoSmithKline), revisión 12/2025, secciones 4.3, 4.4 y 4.5